High efficacy of therapeutic equine hyperimmune antibodies against SARS-CoV-2 variants of concern

  1. Andres Moreira-Soto
  2. Mauricio Arguedas
  3. Hebleen Brenes
  4. Willem Buján
  5. Eugenia Corrales-Aguilar
  6. Cecilia Díaz
  7. Ann Echeverri
  8. Marietta Flores-Díaz
  9. Aarón Gómez
  10. Andrés Hernández
  11. María Herrera
  12. Guillermo León
  13. Román Macaya
  14. Arne Kühne
  15. José Arturo Molina-Mora
  16. Javier Mora
  17. Alfredo Sanabria
  18. Andrés Sánchez
  19. Laura Sánchez
  20. Álvaro Segura
  21. Eduardo Segura
  22. Daniela Solano
  23. Claudio Soto
  24. Jennifer L. Stynoski
  25. Mariángela Vargas
  26. Mauren Villalta
  27. Chantal B E M Reusken
  28. Christian Drosten
  29. José María Gutiérrez
  30. Alberto Alape-Girón
  31. Jan Felix Drexler
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

SARS-CoV-2 variants of concern (VoC) show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies. We tested therapeutic equine polyclonal antibodies (pAbs) against four VoC (alpha, beta, epsilon and gamma). We show that equine pAbs efficiently neutralize VoC, suggesting they are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.

Related articles

Related articles are currently not available for this article.